Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology – Yahoo Finance

CAMBRIDGE, Mass., October 03, 2021–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced an e-poster presentation of clinical results from the TOPAZ Phase 2 trial (NCT03921528) that evaluated apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA) at the 25th World Congress of Neurology (WCN) taking place October 3-7, 2021.
Details for the virtual e-poster are as follows:
Title: Relationship of Pharmacokinetics and Pharmacodynamics to Apitegromab Efficacy in Patients with Later-onset Spinal Muscular Atrophy (Types 2 and 3 SMA): Results from the TOPAZ Study (Poster #EP1150)
This poster will showcase positive correlations between the magnitude of target engagement (as measured by serum levels of latent myostatin) and motor function improvements following treatment with apitegromab.
Time: Virtual e-posters are available for viewing for the duration of the congress (October 3-7, 2021) and will be available on demand for 3 months post conference.
About Apitegromab
Apitegromab is a selective inhibitor of the activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA). Myostatin, a member of the TGFβ superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans. Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA. The U.S. Food and Drug Administration (FDA) has granted Fast Track (FTD), Orphan Drug (ODD) and Rare Pediatric Disease (RPD) designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for the treatment of SMA. The efficacy and safety of apitegromab have not been established and apitegromab has not been approved for any use by the FDA or any other regulatory agency.
About SMA
Spinal muscular atrophy (SMA) is a rare, and often fatal, genetic disorder that typically manifests in young children. An estimated 30,000 to 35,000 patients are afflicted with SMA in the United States and Europe. It is characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk and progressive muscle weakness. The underlying pathology of SMA is caused by insufficient production of the SMN (survival of motor neuron) protein, essential for the survival of motor neurons, and is encoded by two genes, SMN1 and SMN2. While there has been progress in the development of therapeutics that address the underlying SMA genetic defect, via SMN-dependent pathways, there continues to be a high unmet need for therapeutics that directly address muscle function.
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab, SRK-181, and other product candidates and indication selection and development timing, its cash runway, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include preclinical and clinical data, including the results from the Phase 2 trial of apitegromab, are not predictive of, are inconsistent with, or more favorable than, data generated from future clinical trials of the same product candidate, including the planned Phase 3 trial of apitegromab in SMA, Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock’s nonclinical and preclinical studies and clinical trials, information provided or decisions made by regulatory authorities, competition from third parties that are developing products for similar uses, Scholar Rock’s ability to obtain, maintain and protect its intellectual property, the success of Scholar Rock’s current and potential future collaborations, including its collaboration with Gilead, Scholar Rock’s dependence on third parties for development and manufacture of product candidates including to supply any clinical trials, Scholar Rock’s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, and the impacts of public health pandemics such as COVID-19 on business operations and expectations, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.
View source version on
Scholar Rock Contacts:
Catherine Hu
[email protected]
Ariane Lovell
Finn Partners
[email protected]
Related Quotes
A third Alaska hospital has instituted crisis protocols that would allow it to ration care if needed as the state recorded the worst COVID-19 diagnosis rates in the U.S. in recent days
The electric-vehicle maker provided a record number of vehicles in third quarter amid flagging global auto sales.
Are we seeing a major shift into oral medications for COVID? Our Foolish roundtable picks three of the strongest stocks in this rising subsector.
For vaccine leaders Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE), the coronavirus vaccine market represents more than $50 billion this year. Moderna expects $20 billion in vaccine sales. And Pfizer and its partner BioNTech (NASDAQ: BNTX) will split profits after taking in $33.
Building an intuitive understanding of these warning signs is critical for success with pharma stocks.
(Bloomberg) — Makers of vaccines and other coronavirus treatments dropped in Asia after Merck & Co. said its experimental pill cuts the risk of hospitalization and death from Covid-19 in half. Most Read from BloombergChristmas at Risk as Supply Chain ‘Disaster’ Only Gets WorseReshaped by Crisis, an ‘Anti-Biennial’ Reimagines ChicagoThis Is What Europe’s Green Future Looks LikeWall Street Titans Warn of the Next Big Risks for InvestorsAn Unapologetic Old Boys’ Network Is Costing Australia Billio
Merck and Ridgeback Therapeutics Inc.’s experimental oral antiviral treatment is being heralded as a pill with major upside potential in the fight against the COVID-19 pandemic. “It certainly is likely that some people will take, if you will, refuge that should they become infected, a pill might be available that could help them avert serious disease,” said Dr. William Schaffner, a professor at Vanderbilt University Medical Center’s Infectious Diseases Division. “We are seeing this happen already with monoclonal antibody treatments,” he said.
Shares of India's Divi's Laboratories Ltd, which makes the main ingredient of Merck & Co's experimental antiviral pill, soared 10% on Monday, after the pharmaceutical giant reported positive clinical trial results for the drug. Global drugmaker Merck and partner Ridgeback Biotherapeutics on Friday said molnupiravir could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, according to the data released by the companies hailed as a "potential breakthrough" by experts. The news sent Divi shares up as much as 10% to a record high, which boosted the Nifty Pharma Index 2.4% to an all time peak.
Merck on Friday announced that its new pill to treat COVID-19 reduced the risk of hospitalization and death by about 50%. Merck plans to seek emergency authorization for the antiviral pills to be used in the United States. Here’s what you need to know. Who will get the pills? Sign up for The Morning newsletter from the New York Times The pills are meant for people who are sick with COVID but are not in the hospital. Merck’s Phase 3 clinical trial enrolled only unvaccinated people who were consid
Those figures are up from the 394,690,283 vaccine doses that the CDC said had gone into arms by Saturday out of 478,362,045 doses delivered. The CDC tally includes two-dose vaccines from Moderna and Pfizer/BioNTech, as well as Johnson & Johnson's one-shot vaccine. About 5.3 million people have received an additional dose of either Pfizer or Moderna's vaccine since Aug. 13, when the U.S. authorized a third dose of the vaccines for people with compromised immune systems who are likely to have weaker protection from the two-dose regimens.
The White House chief medical adviser stressed, however, that such a pill should in no way replace getting vaccinated against the virus.
The nation’s top infectious disease expert called the results of a recent study “really quite impressive.”
BANGKOK (Reuters) -Thailand's government is in talks with U.S. drugmaker Merck & Co to purchase 200,000 courses of the company's experimental antiviral pill for COVID-19 treatment, a Thai official said on Monday. Many Asian countries are scrambling to lock in supplies of the potential treatment early after they lagged behind Western nations in COVID-19 vaccine rollouts, hit by tight supplies. South Korea, Taiwan and Malaysia said they are all in talks to buy Merck's potential treatment, while the Philippines, which is running a trial on the pill, said it hopes its domestic study would allow access to the treatment.
The global tally for the coronavirus-borne illness climbed above 234 million on Saturday, while the death toll rose above 4.79 million, according to
The light bulb hanging from the ceiling flickered on and off, infuriating the technician in this remote Ugandan town as he checked the refrigerators filled with vaccine doses to confirm they were still working. If the power supply didn’t stabilize, he said, he would have to requisition fuel and start the generator. “It keeps going on and off, like a disco light,” said the technician, Tony Elong.
While scientists are divided over the need for booster shots when so many people in the United States and other countries remain unvaccinated, the Biden administration announced the push for an extra dose in August as part of an effort to shore up protection against the highly transmissible Delta variant. The U.S. Food and Drug Administration (FDA) last week scheduled an Oct. 15 meeting of its expert advisory committee to discuss whether to grant emergency use authorization for a booster shot of J&J's vaccine. Over 15 million Americans have received J&J's vaccine, which is administered as a single dose, according to the latest data from the Centers for Disease Control and Prevention.
A game-changing pill from Rani Therapeutics may offer an easier alternative to fight debilitating diseases.
North Carolina missed out on what's described as a 3,600-acre campus that will hold a battery manufacturing plant, a supplier park and a Ford assembly plant.
Asian markets were mixed on Monday, with Shanghai closed for the National Day holiday. Hong Kong’s benchmark shed more than 2% after troubled property developer China Evergrande’s shares were suspended from trading. The company did not say why, but a Chinese financial news service, Cailian, said another major developer was planning to buy Evergrande's property management unit.
The direction of the December E-mini S&P 500 Index early Monday is likely to be determined by trader reaction to 4366.00.